Where does Genoimmune Therapeutics Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Genoimmune Therapeutics Co., Ltd. ranks #40,400 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Genoimmune Therapeutics Co., Ltd. hold?

Genoimmune Therapeutics Co., Ltd. holds 6 US utility patents granted between 2021 and 2023, spanning 6 technology areas.

What is Genoimmune Therapeutics Co., Ltd.'s Innovation Score?

Genoimmune Therapeutics Co., Ltd. has an Innovation Score of 33.6 out of 100 (45th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Genoimmune Therapeutics Co., Ltd. focus on?

Genoimmune Therapeutics Co., Ltd.'s top technology area is C07K (Peptides) with 6 patents, ranking #1,362 of 3,615 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Genoimmune Therapeutics Co., Ltd.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Genoimmune Therapeutics Co., Ltd..

What does claim depth mean for Genoimmune Therapeutics Co., Ltd.'s patents?

Genoimmune Therapeutics Co., Ltd.'s patents average 8.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Genoimmune Therapeutics Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Genoimmune Therapeutics Co., Ltd.

USPTO PatentsView assignee record - 6 granted patents across 6 technology areas, recorded in grant years 2021–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Genoimmune ranks #40,400 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 6 technology areas.

#40,400
of 49,997 US assignees by volume: 45th percentile
by Innovation Score (33.6/100): 8.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R40400 · Foreign Corporation #40,400 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #40,400/49,997
PHOTO-FINISH Gene Signal…
CPC-NARROW C07K · 6 areas
INNOV-THIN 33.6/100
CLAIMS-PAR 8.2 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2023 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Gene Signal International SA (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Genoimmune’s 33.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (20%) Velocity 13.3 pts (40%) Breadth 8.7 pts (26%) Claim depth 4.9 pts (15%)

Qualcomm Incorporated · highest

85
Genoimmune Therapeut… · this assignee

34
3D Lighting… · lowest

7

What this shows Genoimmune's Innovation Score is 33.6/100 (45th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Genoimmune?

Each dot is one of Genoimmune’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Genoimmune’s own 8.2 claims/patent is at or below the 17.7 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Genoimmune vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Genoimmune's grants concentrate

Genoimmune Therapeutics Co., Ltd. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2022. By volume, Genoimmune sits between Gene Signal International SA and Geospectrum Technologies Inc..

Genoimmune's three-year grant acceleration

Genoimmune Therapeutics Co., Ltd. shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Gene Signal Inter…

6
Generation Brands

6
Genkyotex

6
Gennext

6
Genticel

6
GEO Fossil Fuels

6
GEO M Martin

6
Geospectrum

6
Genoimmune Therap… ◀

6

What this shows Genoimmune holds 6 patents at rank #40,372, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Genoimmune

By rank, the assignees closest to #40,372 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Genoimmune's primary technology class.

Genoimmune's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 45th percentile higher than 45% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Genoimmune Therapeutics Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	2	33.3%
2022	1	16.7%
2023	3	50.0%

Which technologies does Genoimmune Therapeutics Co., Ltd. patent most?

C07K - Peptides 6

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 6

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Genoimmune Therapeutics Co., Ltd.'s patent record in context - here's where to go next.

Genoimmune Therapeutics Co., Ltd.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #40,400 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Genoimmune Therapeutics Co., Ltd. against Gene Signal International SA, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.